表紙
市場調查報告書
商品編碼
1040462

全球子宮內膜異位症市場(2021-2027)

Endometriosis Market 2021-2027

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在預測期內,全球子宮內膜異位症市場預計將以 3.0% 的顯著複合年增長率增長。該市場的主要驅動力是增加對研究和創新的投資。

在 COVID-19 大流行期間市場低迷,因為大多數經濟活動在 2020 年第一和第二季度停止。此外,COVID-19 中斷了與患者治療相關的醫院就診和門診機會,導致診斷延遲。此外,各種手術治療也被推遲。

本報告調查了全球子宮內膜異位症市場、市場概況、市場推動因素/抑制因素分析、COVID-19 的影響、市場機會、藥物類型/診斷/治療。□提供系統信息,例如分銷渠道、按地區進行的市場分析,以及主要公司的簡介。

目錄

第 1 章報告摘要

第 2 章市場概覽和洞察

  • 調查範圍
  • 分析師洞察和當前市場趨勢

第三章競爭形勢

  • 主要公司分析
    • 雅培實驗室
    • 艾伯維公司
    • Myovant Sciences GmbH
    • 輝瑞公司
    • 武田製藥株式會社
  • 關鍵戰略分析
  • COVID-19 對大公司的影響

第 4 章市場決定因素

  • 促進因素
  • 抑製器
  • 市場機會

第 5 章市場細分

  • 子宮內膜異位症的全球市場:按藥物類型
    • 促性腺激素釋放激素激動劑
    • 非甾體抗炎藥
    • 孕激素
    • 口服避孕藥
  • 子宮內膜異位症的全球市場:通過診斷
    • 超聲波
    • 內部檢查
    • 腹腔鏡
    • 磁共振成像 (MRI)
    • 宮腔鏡檢查
    • 子宮超聲
  • 子宮內膜異位症的全球市場:按治療分類
    • 激素療法
    • 疼痛管理
  • 子宮內膜異位症的全球市場:按分銷渠道
    • 醫院
    • 藥店
    • 零售藥店
    • 郵購藥房
    • 電子商務

第6章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他領域

第 7 章公司簡介

  • Allergen PLC
  • Addex Therapeutics
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Debiopharm International SA
  • Evestra Inc.
  • Ipsen Pharma
  • Johnson & Johnson Services Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Neurocrine Biosciences, Inc.
  • ObsEva SA
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • ValiRx PLC
目錄
Product Code: OMR2024013

Global Endometriosis Market Size, Share &Trends Analysis Report By Drug Type (Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drug, Progestin, and Oral Contraceptive Pills), By Diagnosis (Ultrasound, Pelvic Exam, Laparoscopy, Magnetic Resonance Imaging (MRI), Hysteroscopy, and Sonohysterography), By Treatment (Hormonal Therapy and Pain Management), and By Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, Mail Order Pharmacies, and E-Commerce)Forecast Period, 2021-2027

The global endometriosis market is anticipated to grow at a substantial CAGR of 3.0% during the forecast period. The market is set to display impressive growth during the forecast period with some key trends emerging, such as the growing focus on investment in research and technological innovations at a high rate.

The global endometriosis market suffered a downfall during the COVID-19 pandemic as most of the economic activities were halted during Q1 and Q2 2020. Timings related to visiting of hospital and treatment for the patients were also interrupted that had resulted in a delay of diagnosis due to the COVID-19 Pandemic. Additionally, various surgical treatments were also postponed.

The global endometriosis market is segmented based on drug type, diagnosis, treatment, and distribution channel. Based on the drug type segment, the market is segmented into gonadotropins releasing hormone agonists, non-steroidal anti-inflammatory drugs, progestin, and oral contraceptive pills. Based on the diagnosis segment, the market is segmented into ultrasound, pelvic exam, laparoscopy, magnetic resonance imaging (MRI), hysteroscopy, and sonohysterography. Based on the treatment segment, the market is segmented into hormonal therapy and pain management. Further, based on the distribution channel segment, the market is bifurcated into hospital pharmacies, drug stores, retail pharmacies, mail-order pharmacies, and e-commerce

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific is expected to have the fastest-growing region in the market. The growing number of generic manufacturers in which was once a stronghold of the US and a few European economies such as France, Italy, and Germany, is set to expand to emerging economies, in the Asia-Pacific region. The increasing disposable income in the Asian economies of Japan, South Korea, Taiwan, and China, which is set to increase the treatment for endometriosis

Further, Abbott Laboratories, AbbVie Inc., Bayer AG, AstraZeneca plc, Pfizer Inc., Takeda Pharmaceutical Company Ltd., among others are the key players in the market, which are adopting different strategies such as new product launches and approvals, mergers and acquisitions, partnerships and collaborations, among others. For instance, in January 2020, Bayer AG had entered into a new five-year research agreement with one of the German biotech companies named Evotec with an emphasis on polycystic ovary syndrome (PCOS). Additionally, the companies were also working on drug candidates for endometriosis and adding PCOS that will support the health conditions of around 500 million women across the globe.

Research Methodology

The market study of the global endometriosis market is incorporated by extensive primary and secondary research conducted by the research team at OMR Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market

Whitepapers, research papers, and news blogs

Company websites and their product catalog

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Endometriosis Market Research And Analysis By Drug Type

Global Endometriosis Market Research And Analysis By Diagnosis

Global Endometriosis Market Research And Analysis By Treatment

Global Endometriosis Market Research And Analysis By Distribution Channel

The Report Covers

Comprehensive research methodology of the global endometriosis market

This report also includes a detailed and extensive market overview with key analyst insights

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations

Analysis of regional regulations and other government policies impacting the global endometriosis market

Insights about market determinants that are stimulating the global endometriosis market

Detailed and extensive market segments with the regional distribution of forecasted revenues

Extensive profiles and recent developments of market players

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Endometriosis Market Industry
  • Recovery Scenario of Global Endometriosis Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Abbott Laboratories
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. AbbVie, Inc.
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Myovant Sciences GmbH
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Pfizer, Inc.
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. Takeda Pharmaceutical Company Ltd.
      • 3.1.5.1. Overview
      • 3.1.5.2. Financial Analysis
      • 3.1.5.3. SWOT Analysis
      • 3.1.5.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Endometriosis Market by Drug Type
    • 5.1.1. Gonadotropins Releasing Hormone Agonists
    • 5.1.2. Non-Steroidal Anti-Inflammatory Drug
    • 5.1.3. Progestin
    • 5.1.4. Oral Contraceptive Pills
  • 5.2. Global Endometriosis Market by Diagnosis
    • 5.2.1. Ultrasound
    • 5.2.2. Pelvic Exam
    • 5.2.3. Laparoscopy
    • 5.2.4. Magnetic Resonance Imaging (MRI)
    • 5.2.5. Hysteroscopy
    • 5.2.6. Sonohysterography
  • 5.3. Global Endometriosis Market by Treatment
    • 5.3.1. Hormonal Therapy
    • 5.3.2. Pain Management
  • 5.4. Global Endometriosis Market by Distribution Channel
    • 5.4.1. Hospital
    • 5.4.2. Drug Stores
    • 5.4.3. Retail Pharmacies
    • 5.4.4. Mail Order Pharmacies
    • 5.4.5. E-Commerce

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Allergen PLC
  • 7.2. Addex Therapeutics
  • 7.3. Astellas Pharma Inc.
  • 7.4. AstraZeneca plc
  • 7.5. Bayer AG
  • 7.6. Debiopharm International SA
  • 7.7. Evestra Inc.
  • 7.8. Ipsen Pharma
  • 7.9. Johnson & Johnson Services Inc.
  • 7.10. Kissei Pharmaceutical Co., Ltd.
  • 7.11. Neurocrine Biosciences, Inc.
  • 7.12. ObsEva SA
  • 7.13. Sanofi S.A.
  • 7.14. Teva Pharmaceutical Industries Ltd.
  • 7.15. ValiRx PLC

LIST OF TABLES

  • 1. GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 3. GLOBAL GONADOTROPINS RELEASING HORMONE AGONISTS FORENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUG FOR ENDOMETRIOSIS MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL PROGESTIN FOR ENDOMETRIOSIS MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL ORAL CONTRACEPTIVE PILLSFOR ENDOMETRIOSIS MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSISBY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL ULTRASOUND IN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL PELVIC EXAM IN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL LAPAROSCOPY IN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) IN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL HYSTEROSCOPY IN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL SONOHYSTEROGRAPHY IN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 15. GLOBAL HORMONAL THERAPY FOR ENDOMETRIOSIS MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL PAIN MANAGEMENT FOR ENDOMETRIOSIS MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 18. GLOBALENDOMETRIOSIS IN HOSPITAL MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 19. GLOBALENDOMETRIOSIS IN DRUG STORES MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 20. GLOBAL ENDOMETRIOSIS IN RETAIL PHARMACIES MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 21. GLOBAL ENDOMETRIOSIS IN MAIL-ORDER PHARMACIES MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 22. GLOBALENDOMETRIOSIS IN E-COMMERCE MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
  • 23. GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 24. NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 25. NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 26. NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 27. NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 28. NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 29. EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 30. EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 31. EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 32. EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 33. EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 34. ASIA-PACIFICENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 35. ASIA-PACIFICENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 36. ASIA-PACIFICENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 37. ASIA-PACIFICENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 38. ASIA-PACIFICENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 39. REST OF THE WORLDENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 40. REST OF THE WORLDENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 41. REST OF THE WORLDENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 42. REST OF THE WORLDENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL ENDOMETRIOSIS MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL ENDOMETRIOSIS MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL ENDOMETRIOSIS MARKET, 2021-2027 (%)
  • 4. GLOBAL ENDOMETRIOSIS MARKET SHARE BY DRUG TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL ENDOMETRIOSIS MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
  • 6. GLOBAL ENDOMETRIOSIS MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
  • 7. GLOBAL ENDOMETRIOSIS MARKET SHARE BY DISTRIBUTION CHANNEL, 2020 VS 2027 (%)
  • 8. GLOBAL GONADOTROPINS RELEASING HORMONE AGONISTS FOR ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUG FOR ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL PROGESTIN FOR ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL ORAL CONTRACEPTIVE PILLSFOR ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL ULTRASOUND IN ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL PELVIC EXAM IN ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL LAPAROSCOPY IN ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) IN ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 16. GLOBAL HYSTEROSCOPY IN ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 17. GLOBAL SONOHYSTEROGRAPHY IN ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 18. GLOBAL HORMONAL THERAPY FOR ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 19. GLOBAL PAIN MANAGEMENT FOR ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 20. GLOBALENDOMETRIOSIS IN HOSPITAL MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 21. GLOBALENDOMETRIOSIS IN DRUG STORES MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 22. GLOBAL ENDOMETRIOSIS IN RETAIL PHARMACIES MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 23. GLOBAL ENDOMETRIOSIS IN MAIL-ORDER PHARMACIES MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 24. GLOBALENDOMETRIOSIS IN E-COMMERCE MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 25. US ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. CANADA ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. UK ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. FRANCE ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. GERMANY ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. ITALY ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. SPAIN ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. ROE ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. INDIA ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 34. CHINA ENDOMETRIOSIS MARKETSIZE, 2020-2027 ($ MILLION)
  • 35. JAPAN ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 36. ROAPAC ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 37. REST OF THE WORLD ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)